
    
      Subjects will receive nivolumab, ipilimumab and cabozantinib until either disease
      progression, the occurrence of unacceptable drug-related toxicity or for other reason(s) for
      subject withdrawal. Treatment will continue for up to 2 years unless there is disease
      progression, drug intolerance or other reason for discontinuation discussed with the
      principal investigator (PI). Patients with ongoing complete or partial response may
      discontinue therapy after 1 year on treatment at the discretion of the treating investigator.
    
  